The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 12, 2006, Pages 2731-2737

  Lalloyer, Fanny ^a,b,c   Fiévet, Catherine ^a,b,c   Lestavel, Sophie ^a,b,c   Torpier, Gérard ^a,b,c   Van Der Veen, Jelske ^d   Touche, Véronique ^a,b,c   Bultel, Stéphanie ^a,b,c   Yous, Saïd ^e   Kuipers, Folkert ^d   Paumelle, Réjane ^a,b,c   Fruchart, Jean Charles ^a,b,c   Staels, Bart ^a,b,c   Tailleux, Anne ^a,b,c  

^a INSTITUT PASTEUR DE LILLE   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

Author keywords

Atherosclerosis; Cholesterol homeostasis; Intestinal cholesterol absorption; Rexinoid; Triglycerides

Indexed keywords

BEXAROTENE;

ABSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GENE EXPRESSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INTESTINE ABSORPTION; MACROPHAGE; METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD13; APOLIPOPROTEIN E2; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; FEMALE; GENE EXPRESSION REGULATION; HOMEOSTASIS; INTESTINAL ABSORPTION; LIPOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; RETINOID X RECEPTORS; TETRAHYDRONAPHTHALENES; TRIGLYCERIDES;

EID: 33751186899     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000248101.93488.84     Document Type: Article

References (38)

1. Farol LT, Hymes KB. Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004;4:180-188.
2. Smit JV, Franssen ME, de Jong EM, Lambert J, Roseeuw DI, De Weert J, Yocum RC, Stevens VJ, van de Kerkhof PC. A phase II multicenter clinical trial of systemic bexarotene in psoriasis. J Am Acad Dermatol. 2004;51:249-256.
3. Staels B. Regulation of lipid and lipoprotein metabolism by retinoids. J Am Acad Dermatol. 2001;45:S158-S167.
4. Streb JW, Miano JM. Retinoids: pleiotropic agents of therapy for vascular diseases? Curr Drug Targets Cardiovasc Haematol Disord. 2003;3:31-57.
5. Szanto A, Narkar V, Shen Q, Uray IP, Davies PJ, Nagy L Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ. 2004;11(Suppl 2):S126-S143.:S126-S143.
6. Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro JM, Paterniti JR, Mangelsdorf DJ, Heyman RA, Auwerx J. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci U S A. 2001;98:2610-2615.
7. Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fievet C. Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. Trends Pharmacol Sci. 2003;24:530-534.
8. Altmann SW, Davis HR, Jr., Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;%20;303:1201-1204.
9. Kramer W, Girbig F, Corsiero D, Pfenninger A, Frick W, Jahne G, Rhein M, Wendler W, Lottspeich F, Hochleitner EO, Orso E, Schmitz G. Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane. J Biol Chem. 2005;280:1306-1320.
10. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest. 1998;102:130-135.
11. Lubet RA, Christov K, Nunez NP, Hursting SD, Steele VE, Juliana MM, Eto I, Grubbs CJ. Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis. Carcinogenesis. 2005;26:441-448.
12. Attie AD, Krauss RM, Gray-Keller MP, Brownlie A, Miyazaki M, Kastelein JJ, Lusis AJ, Stalenhoef AF, Stoehr JP, Hayden MR, Ntambi JM. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res. 2002;43:1899-1907.
13. Hennuyer N, Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fievet C. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol. 2005;25:1897-1902.
14. Davis HR, Jr., Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol. 2001;21:2032-2038.
15. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR, Jr., Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005;102:8132-8137.
16. van der Veen JN, Kruit JK, Havinga R, Baller JF, Chimini G, Lestavel S, Staels B, Groot PH, Groen AK, Kuipers F. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res. 2005;46:526-534.
17. Murdoch D, Scott LJ. Ezetimibe/Simvastatin: a review of its use in the management of hypercholesterolemia. Am J Cardiovasc Drugs. 2004;4:405-422.
18. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem. 2005;280:12710-12720.
19. Kramer W, Glombik H, Petry S, Heuer H, Schafer H, Wendler W, Corsiero D, Girbig F, Weyland C. Identification of binding proteins for cholesterol absorption inhibitors as components of the intestinal cholesterol transporter. FEBS Lett. 2000;487:293-297.
20. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science. 2000;289:1524-1529.
21. McNeish J, Aiello RJ, Guyot D, Turi T, Gabel C, Aldinger C, Hoppe KL, Roach ML, Royer LJ, de Wet J, Broccardo C, Chimini G, Francone OL. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci U S A. 2000;97:4245-4250.
22. Drobnik W, Lindenthal B, Lieser B, Ritter M, Christiansen WT, Liebisch G, Giesa U, Igel M, Borsukova H, Buchler C, Fung-Leung WP, Von Bergmann K, Schmitz G. ATP-binding cassette transporter A1 (ABCA1) affects total body sterol metabolism. Gastroenterology. 2001;120:1203-1211.
23. Mulligan JD, Flowers MT, Tebon A, Bitgood JJ, Wellington C, Hayden MR, Attie AD. ABCA1 is essential for efficient basolateral cholesterol efflux during the absorption of dietary cholesterol in chickens. J Biol Chem. 2003;278:13356-13366.
24. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest. 2006;116:1052-1062.
25. Duval C, Touche V, Tailleux A, Fruchart JC, Fievet C, Clavey V, Staels B, Lestavel S. Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem Biophys Res Commun. 2006;340:1259-1263.
26. Yu L, York J, Von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Biol Chem. 2003;278:15565-15570.
27. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 2003;9:213-219.
28. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999;104:R25-R31.
29. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A. 2004;101:9774-9779.
30. Zhu L, Bisgaier CL, Aviram M, Newton RS. 9-cis retinoic acid induces monocyte chemoattractant protein-1 secretion in human monocytic THP-1 cells. Arterioscler Thromb Vasc Biol. 1999;19:2105-2111.
31. Kang BY, Chung SW, Kim SH, Kang SN, Choe YK, Kim TS. Retinoid-mediated inhibition of interleukin-12 production in mouse macrophages suppresses Th1 cytokine profile in CD4(+) T cells. Br J Pharmacol. 2000;130:581-586.
32. Tenno T, Botling J, Oberg F, Jossan S, Nilsson K, Siegbahn A. The role of RAR and RXR activation in retinoid-induced tissue factor suppression. Leukemia. 2000;14:1105-1111.
33. Mou L, Lankford-Turner P, Leander MV, Bissonnette RP, Donahoe RM, Royal W. RXR-induced TNF-alpha suppression is reversed by morphine in activated U937 cells. J Neuroimmunol. 2004;147:99-105.
34. Uchimura K, Nakamuta M, Enjoji M, Irie T, Sugimoto R, Muta T, Iwamoto H, Nawata H. Activation of retinoic X receptor and peroxisome proliferator- activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. Hepatology. 2001;33:91-99.
35. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, Salmona M. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol. 2001;21:1327-1332.
36. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 2000;14:2831-2838.
37. Shimizugawa T, Ono M, Shimamura M, Yoshida K, Ando Y, Koishi R, Ueda K, Inaba T, Minekura H, Kohama T, Furukawa H. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem. 2002;277:33742-33748.
38. Gotto AM, Jr. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol. 1998;82:22Q-25Q.